Document is current
Any future updates will be listed below
-
Authors
Rodríguez-Lobato, Luis Gerardo https://orcid.org/0000-0001-5694-0921
de Daniel, Anna https://orcid.org/0009-0007-7568-2527
Carro Arostegui, Itziar
Arribas Castro, Iago
Gironella, Mercedes https://orcid.org/0000-0002-8106-8909
Verge, Jordi
Escoda, Lourdes
Tolosa, Carles https://orcid.org/0000-0003-0706-9046
Martí-Tutusaus, Josep María
Baca, Cristina
Abella, Eugènia
Motlló, Cristina
López-Pardo, Jordi
Oriol, Albert https://orcid.org/0000-0001-6804-2221
Castillo-Girón, Carlos
Tovar, Natalia
Rosiñol, Laura https://orcid.org/0000-0002-2534-9239
Cibeira, M. Teresa
Sureda, Anna https://orcid.org/0000-0002-1238-6970
Fernández de Larrea, Carlos https://orcid.org/0000-0003-4930-9255
-
Funding
Funding for this research was provided by:
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (PI22/00647)
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (PI25/00571)
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (PI22/00647)
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (PI25/00571)
CRIS Cancer Foundation, grant number: TRANSPHYSTALENT_23_6
- License Information
-
More Information
Article History
Received: 2 March 2026
Revised: 19 June 2026
Accepted: 5 July 2026
First Online: 25 July 2026
Ethics
Competing interests: Luis Gerardo Rodríguez-Lobato: Honoraria and travel grants from Janssen, Amgen, GSK, BMS, Sanofi, and Menarini Stemline; Anna de Daniel: Honoraria from Janssen, travel grants from Sanofi, Janssen, Binding Side; M. Teresa Cibeira: Honoraria from Janssen, Sanofi, GSA, Amgen, and Pfizer; Laura Rosiñol: Honoraria from BMS, Celgene, Amgen, Takeda, Sanofi, Janssen, GSK; Josep María Martí Tutusaus: Honoraria from Janssen, Pfizer and Menarini Stemline; Anna Sureda: Honoraria: Takeda, BMS/Celgene, MSD, Novartis, Gilead Kite, Sanofi, Roche, GenMab, Abbvie, Jazz Pharmaceuticals; Consultancy: Takeda, BMS/Celgene, Novartis, Janssen, Gilead, Sanofi, GenMab, Abbvie; Speaker’s Bureau: Takeda; Research Support: Takeda; Carlos Fernández de Larrea: Consultancy: BeiGene, Sanofi, GSK, BMS, Janssen; Honoraria: BeiGene, Pfizer, Sanofi, GSK, Takeda, BMS, Janssen; Research Funding: Takeda, Amgen, BMS, Janssen. The rest of the authors declare no competing interests.
